The US Food and Drug Administration (FDA) has for Becton, Dickinson and Company鈥檚 (BD) updated BD Alaris Infusion System.
The approval encompasses the latest hardware advancements for point-of-care units (PCU), patient-controlled analgesia (PCA) pumps, large volume pumps, syringe pumps and respiratory monitoring and auto-identification modules.
Furthermore, the clearance covers a new BD Alaris Infusion System software version with improved cybersecurity and interoperability features.
These features facilitate intelligent, connected care with the most used electronic medical record (EMR) systems.
It is claimed to be the only system with a centralised user interface for up to four modules for all major types of infusions.
The infusions include syringe pumps, large-volume pumps and PCA therapy with optional respiratory monitoring. One interface controls all modules with a common PCU.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHospitals and health systems can use the comprehensive infusion system for optimising their workflows and easily scaling their infusion requirements across an entire integrated delivery network besides offering interoperability with EMRs.
In addition, the new system can transmit data to the BD HealthSight platform, facilitating comprehensive enterprise medication management.
BD chairman, CEO and president Tom Polen said: 鈥淲e are deeply committed to ensuring clinicians can continue to rely on our market-leading system to meet today’s most critical infusion needs.
鈥淭he features and enhancements incorporated into the updated聽BD Alaris Infusion System聽and subject to this clearance reinforce our advancements in smart, connected care, which delivers greater benefit to clinicians and patients and helps improve health care system efficiency through better care coordination and utilisation of actionable information.鈥�
